Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 26, 2023; 11(21): 5122-5128
Published online Jul 26, 2023. doi: 10.12998/wjcc.v11.i21.5122
Primary ovarian angiosarcoma: Two case reports and review of literature
Ying Zhou, Yi-Wen Sun, Xiao-Yang Liu, Dan-Hua Shen
Ying Zhou, Yi-Wen Sun, Xiao-Yang Liu, Dan-Hua Shen, Department of Pathology, Peking University People’s Hospital, Beijing 100044, China
Author contributions: Zhou Y and Sun YW designed the research study; Zhou Y, Sun YW and Liu XY performed the research; Zhou Y and Shen DH wrote the manuscript; and all authors have read and approve the final manuscript.
Informed consent statement: Written informed consent has been obtained from the patient for publication of this case report.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dan-Hua Shen, Doctor, Chief Physician, Department of Pathology, Peking University People’s Hospital, No. 11 Xizhimen South Street, Beijing 100044, China. shendanhua@pkuph.edu.cn
Received: April 8, 2023
Peer-review started: April 8, 2023
First decision: May 31, 2023
Revised: June 5, 2023
Accepted: June 27, 2023
Article in press: June 27, 2023
Published online: July 26, 2023
Core Tip

Core Tip: Angiosarcoma (AS) is a rare and highly aggressive type of soft tissue that most commonly arises in deep soft tissues. Alternative therapeutic strategies such as targeted therapies and anti-programmed cell death 1/programmed cell death ligand 1 therapy may be promising for primary ovarian AS.